Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1462.65 | 85,035 Cr | 24.26 | 2.24 | 0.00 | 9.25 | 11.76 | 5.99 | ||
1393.00 | 75,122 Cr | 84.52 | 14.17 | 0.14 | 16.77 | 16.14 | 8.47 | ||
416.40 | 67,559 Cr | 175.21 | 1.99 | 0.12 | 1.14 | 3.64 | 0.58 | ||
5301.00 | 63,388 Cr | 27.54 | 4.59 | 1.00 | 16.66 | 18.61 | 11.27 | ||
2147.30 | 60,514 Cr | 44.44 | 5.76 | 0.12 | 28.08 | 32.70 | 6.84 | ||
26030.05 | 55,407 Cr | 35.70 | 11.61 | 1.82 | 32.51 | 42.54 | 23.87 | ||
1621.60 | 40,924 Cr | 35.86 | 5.07 | 0.37 | 14.15 | 18.58 | 9.63 | ||
| Median: 7 Co. | — | 1621.60 | 63,388 Cr | 35.86 | 5.07 | 0.14 | 16.66 | 18.58 | 8.47 |
Biocon Ltd (BIOCON) is currently trading at 418.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets. The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26. Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus. Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Over the past 52 weeks, Biocon Ltd has traded between a low of ₹331.00 and a high of ₹440.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biocon Ltd has a market capitalization of approximately 67,559.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 175.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 67,559.44 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biocon Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biocon Ltd is 175.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Biocon stated the resolution in the postal ballot notice dated May 02, 2025 was approved with requisite majority and deemed passed on June 04, 2025.
Remote e-voting commenced on May 09, 2026 and is scheduled to conclude on June 07, 2026.
The changes are set to take effect from April 1, 2026, with the outgoing CEO and interim CFO resignations effective at the close of business on March 31, 2026.
Biocon revised the preferential issue price to ₹376.41 per share, with a floor price of ₹373.08.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets.
The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26.
Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus.
Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Pharmaceuticals & Biotechnology
Pharmaceuticals
67,559 Cr
Low Risk
175.2
34.1
2.4
2.0
440.30
331.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
8
Bullish
4
Bearish
8
Neutral
8
Bullish
30
Bearish
6
Neutral
0
Bullish
26
Postal ballot outcome
Biocon Limited announced postal ballot results (deemed passed June 7, 2026): shareholders approved revision of Kiran Mazumdar‑Shaw’s remuneration, appointment of Shreehas Pradeep Tambe as CEO & MD, a preferential equity issuance and multiple director appointments.
Postal Ballot Outcome
Biocon reported that all postal ballot resolutions were approved on June 7, 2026, including revised remuneration for Executive Chairperson Kiran Mazumdar-Shaw; appointment of Shreehas P. Tambe as CEO & MD; preferential equity issuance; and multiple director appointments.
Postal ballot results
Biocon reported postal ballot voting results and the Scrutinizer's Report: all resolutions were approved (deemed passed June 7, 2026), including remuneration revision for Executive Chairperson Kiran Mazumdar‑Shaw, appointment of Shreehas Tambe as CEO & MD, a preferential equity issuance and multiple director appointments.
Postal Ballot Results
Biocon filed voting results and scrutinizer's report: members approved on June 7, 2026 the revision of Kiran Mazumdar‑Shaw’s remuneration, appointment of Shreehas Tambe as CEO & MD, preferential equity issuance and multiple director appointments/re‑appointments.
